The National Institute of Allergy and Infectious Diseases of the NIH
announced it will fund 5-year grants to three HIV research teams for a total of
$14 million within the first year.
The grants are part of the
Martin Delaney Collaboratory, designed to create
public-private partnerships in HIV care, according to an NIH press release.
Martin Delaney was a true hero in the fight against
HIV/AIDS, and he believed, as we do, that progress
toward a cure for HIV/AIDS can be made through partnerships among scientists in
government, industry and academia, Anthony S. Fauci, MD, NIAID
director, said in the release.
These new grants, and the collaboratory to which they belong, are
one way in which we honor his memory and advance his vision, Fauci said.
The following research teams will receive the grants:
- Fred Hutchinson Cancer Research Center in Seattle, working with
Sangamo BioSciences Inc., a biopharmaceutical company based in Richmond,
- University of North Carolina at Chapel Hill, working with Merck
Research Laboratories, based in Whitehouse Station, N.J.;
- University of California, San Francisco, and the Vaccine & Gene
Therapy Institute of Florida in Port St. Lucie, Fla., working with Merck
Each team will pursue a unique and complementary approach aimed at
eradicating these remaining HIV reservoirs. To fulfill their role as members of
a collaboratory, the teams will also meet periodically as their research
progresses to find ways to work together, NIH officials wrote in the